Article Details
Retrieved on: 2024-05-13 20:55:36
Tags for this article:
Click the tags to see associated articles and topics
Summary
Sutro Biopharma, a clinical-stage oncology company, reports positive progress on its luveltamab tazevibulin (luvelta) trials and financial growth, bolstering its equity and balance sheet with significant funding and investments, as mentioned in their Form 10-K and highlighted in South San Francisco updates.
Article found on: www.morningstar.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here